Balicatib
Balicatib is an inhibitor of cathepsin K with IC50 value of 1.4nM [1].
Balicatib is highly selective against cathepsin K over cathepsin B, L and S in the in vitro enzyme assay. However, the selectivity is not so high in cell-based enzyme assay. The lysosomotropic character of balicatib results in its accumulation in lysosomes and the subsequent nonselective off-target effects. The off-target effects also cause the skin adverse events of balicatib [1, 2].
As a cathepsin K inhibitor, balicatib is developed for osteoporosis. It has been reported to reduce the biochemical markers of bone resorption and increase bone mineral density in ovariectomized monkeys. In addition, balicatib shows benefits in new bone formation of postmenopausal women [2].
References:
[1] Black WC. Peptidomimetic inhibitors of cathepsin K. 2010;10(7):745-51.
[2] Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009 May;18(5):585-600.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 411.54 |
| Cas No. | 354813-19-7 |
| Formula | C23H33N5O2 |
| Solubility | ≥17 mg/mL in DMSO; insoluble in H2O; ≥2.54 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide |
| SDF | Download SDF |
| Canonical SMILES | CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
